Skip to main content

Table 2 Patient Characteristics in the comparison study (N=62)

From: Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib

 

Afatinib (N=29).

G/E (N=33).

P value

Age, median (range)

66 (36–80)

68 (41–80)

 

Sex (Male/Female)

20/9

9/24

0.0010

Histology (Adenocarcinoma)

29

33

1.0

Smoking (Yes/No)

13/16

8/25

0.0126

Mutation (19del/ L858R)

23/6

17/16

0.0225

Stage (III,IV/postoperative recurrence)

25/4

23/10

0.1208

Treatment with Osimertinib (Yes/No)

9/20

15/18

0.2448

  1. G/E gefitinib/erlotinib